Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Predict S.P.A. Class B ( (IT:PRE) ) just unveiled an announcement.
Predict S.p.A. has appointed long‑standing executive Isabella Cafagna as director of its Digital Healthcare business unit, expanding her remit beyond the Mistral SBU to accelerate the commercial rollout of its augmented reality and robotics solutions for healthcare professionals. The move is designed to strengthen team organization and commercial execution as the division enters a revenue growth phase, building on Cafagna’s track record leading the Mistral SBU, where she oversaw national clinical trials of the company’s patented breath-analysis technology for multiple cancers and occupational exposure, reinforcing Predict’s positioning in innovative, non‑invasive diagnostics and digital health.
Under Cafagna’s leadership, the Mistral platform has been deployed in multicenter trials across Italy for colorectal, lung, prostate, breast, and head‑and‑neck cancers, as well as workplace pollutant exposure, in partnership with leading hospitals and research centers. Management signals that her new role in Digital Healthcare is central to scaling operations and capturing rising market volumes in a highly competitive med‑tech landscape, as Predict seeks to consolidate its results and accelerate growth in cutting-edge diagnostics and digital healthcare solutions.
The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.
More about Predict S.P.A. Class B
Predict S.p.A., founded in 2008 in Bari, is an Italian med‑tech SME focused on in vivo diagnostics, ultrasound and radiology equipment distribution, and advanced breath analysis and digital healthcare solutions. Organized into four strategic business units, it develops technologies such as the Mistral breath-analysis platform, AI-driven robotic assistants, and augmented reality systems for clinicians, while collaborating with major university hospitals and research institutes across Italy.
Average Trading Volume: 28,894
Technical Sentiment Signal: Sell
Current Market Cap: €5.41M
See more insights into PRE stock on TipRanks’ Stock Analysis page.